Recent Finacing
Recent Raise
Diakonos Oncology develops an autologous double-loaded dendritic cell platform combining tumor lysate and tumor-derived mRNA to manufacture DOC1021 for late-stage cancers, advancing Phase 2 glioblastoma and other clinical programs.
